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ABSTRACT
Patients on hemodialysis usually need management of diabetes, hypertension, dyslipidemia,
anemia, and bone mineral disorder. This study was conducted to asses prescribing pattern, to evaluate compliance to treatment guidelines and goals of therapy in hemodialysis patients. This study
was an observational retrospective cohort study; it was conducted at Hebron governmental hospital
/ Palestine. All adult patients on chronic hemodialysis were included. All information were collected from governmental electronic health record (AviCenna HIS program), and patients were asked
to answer some questions. During the study period 158 patients were prescribed 1567 medication
orders with a mean of 9.92±2.94. The majority of the patients (72.2%) had Hypertension. The target predialysis blood pressure was achieved in 77.2% of the patients (70.5% of the males vs 87.3%
of the females; P- value =0.014), and post dialysis blood pressure was achieved in 57.6% cases.
Diabetes was a comorbid disease in 36.7% patients and hemoglobin A1c (HbA1c) test was not performed for these patients. Patients with total cholesterol levels of < 200 mg/dl were 78.3% patients.
Regarding triglycerides levels, 96.2% had levels of < 500 mg/dl. In the management of anemia,
patients who reached goal hemoglobin (Hb) of 11-12 mg/dl according to the national kidney foundation (NKF) guidelines were 8.9% patients only. If kidney disease improving global outcome
(KDIGO) guidelines are used (Hb 9-11.5 mg/dl) the patients in this range were 43.0% cases. Transferrin levels were not measured. Iron was used by 69.9% of the patients, and erythropoietin stimulating agents (ESA) by 5.1% of the patients as it was not available in the hospital. No data was
available for calcium, and parathyroid hormone levels. Target phosphorus level was obtained in
12.0% of the patients according to the NKF guidelines. If serum phosphorus normal range of 2.5–
4.5 mg/dl is used according to KDIGO guidelines, this target was achieved in 4.4% patients only.
The results reflect a poor compliance to treatment guidelines. The target levels for treatment are not
achieved in many HD patients. The medications are not prescribed optimally to the patients and
many investigations and laboratory tests are not performed.
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at an asymptomatic condition detected
only by laboratory testing (3). The popuINTRODUCTION
lation with ESRD is expanding at a rate
of around 7% per year worldwide (4).
Chronic kidney disease (CKD) is a
The increase in ESRD incidence could
growing epidemic worldwide (1). It is
be due to the increase of patients with
associated with poor prognosis, develCKD and the rate of their disease proopment of premature cardiovascular disgression, decreases in competing mortalease and increased mortality (2). Treatity, and/or increasing treatment availament of CKD aims to slow progression
bility (5). The leading cause of ESRD is
to end-stage renal disease (ESRD) and to
diabetes followed by renal vascular disprepare for it. Therapy is usually started
ease, including hypertension (6). The
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maintenance therapy for ESRD is by
renal replacement therapy, through dialysis or kidney transplant. Clinical management of dialysis patients often involves treatment of multiple comorbid
conditions, in which dialysis patients are
prescribed on average 9-10 oral medications and 2-3 parenteral medications (7,
8). Patients on hemodialysis (HD) need
to use a large number of medications to
control their disease complications and
other comorbid diseases. In Palestine,
limited information about this population
is available. To the best of our
knowledge, prescribing pattern and adherence to treatment guidelines in HD
patients were not studied before in our
country, therefore, it would be important
to evaluate current situation and compare it with international guidelines for
treatment to improve the quality of care
provided to HD patients. Findings can
help in developing educational programs
and interventions to improve compliance
with international treatment guidelines in
HD patients.
The aims of this study were to asses
prescribing pattern and to evaluate compliance to treatment guidelines of National Kidney Foundation (NKF) and
Kidney Disease: Improving Global Outcomes (KDIGO) for anemia, bone disease, diabetes mellitus, hypertension and
dyslipidemia in hemodialysis patients in
Hebron governmental hospital and to
evaluate if the outcomes of treatment
(e.g target hemoglobin, calcium, phosphorus, HB A1c, blood pressure (BP),
etc) meet the recommended goals.
MATERIALS AND METHODS
The study was an observational retrospective cohort study. It was carried out at
Hebron governmental hospital /Palestine between the first of March 2014 and the end of
April 2014. Palestinian Ministry of Health
(MOH) is the main health care provider for
the ESRD management in Palestine, where
treatments of ESRD are given free to the patients. According to the Palestinian Ministry
of health report in 2013 there are 800 patients
on HD in the West Bank hospitals with 141

dialysis machines distributed among 10 hemodialysis units (8).
All adult HD patients (158 patients) who
had their HD sessions in that hospital during
the study period and met the inclusion criteria were asked to participate in the study. Exclusion criteria included patients who were
younger than 18 years of age or patients who
required HD for acute renal failure or were
on HD for less than one month.
Data collection form was prepared
after literature review of guidelines and
previous studies. All information were
collected from the governmental electronic health records (AviCenna HIS
program), which was used to identify
chronic HD patients. Verbal consent was
obtained from the patients. All of them
accepted to be involved in the study. The
file for every patient was reviewed;
baseline demographics, comorbid conditions, vital signs, laboratory data, and
information about the medications were
collected. Regarding the medications,
the last medication order was reported
and for the laboratory tests the last reading in the file was documented. Also,
patients were asked to answer some
questions about sociodemoghraphic factors and other medications purchased or
used by them when data were not found
in (AviCenna HIS program).
The study protocol was authorized
by the Institutional Review Boards
(IRB) of An Najah National University
and the Ministry of Health before initiation of this study.
As we do not have our own national
guidelines for treatment of ESRD patients, guidelines by the National Kidney
Foundation
Kidney
Disease/Dialysis
Outcomes
Quality
Initiative
(NKFKDOQI) and Kidney Disease: Improving Global Outcomes
(KDIGO) were
used to compare the practice (medications and target goals) in this study with
these guidelines (Table 1). These guidelines are very well-known and are being
followed in many countries. Treatments
of diabetes, hypertension, dyslipidemia,
anemia and bone disease were included.

Palestinian Medical and Pharmaceutical Journal (PMPJ). 2016; 1(1): 15-24 ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ

Al-Ramahi & Namourah  ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ17

Table (1): Summary of KDOQI and KDIGO clinical practice guidelines.
Recommended medications
Goals
Diabetes
HbA1c of around 7.0%
Insulin regimens
Oral hypoglycemic agents should
be used with caution (e.g. glyburide, glipizide, and glimepride)
Metformin is contraindicated
Hypertension
ACE inhibitors or ARBs should be Predialysis BP <140/90mmHg
preferred
Postdialysis BP <130/80mmHg
Dyslipidemia
Statins are preferred
LDL cholesterol < 100 mg/dL
Triglycerides < 500 mg/d
Statins or statin/ezetimibe combination not to be initiated after HD if
they were not used before
Anemia
Erythropoietin stimulating (ESA) Hb level 11-12 g/dl
agent and iron
Serum ferritin level > 200 ng/mL
Transferin > 20%
Hb level 9-11.5 g/dl
Serum ferritin level > 500 ng/mL
Transferin > 30%
Bone metabolism and disease
Calcium-based phosphate binders Phosphorus 3.5 - 5.5 mg/dL
and non calcium-, containing phos- Corrected total calcium 8.4 - 9.5
phate-binding agents (such as mg/dL
PTH 150 - 300 pg/mL.
sevelamer HCl)
Serum phosphorus and calcium
Active vitamin D
in the normal range
iPTH levels in the range of approximately 2-9 times the upper
normal limit for the assay
Statistical analysis was performed
by using Statistical Package for Social
Sciences (SPSS version 16.0) program.
Descriptive statistics were carried out for
all variables. Mean ± standard deviation
was computed for continuous data. Frequencies (percentages) were calculated
for categorical variables. Categorical
variables were compared using Chisquare. When categorical and continuous
variables were compared; independent
student T test or Mann-Whitney test according to the normality were used. Association between continuous variables

Reference
NKF, 2007
NKF, 2012

NKF, 2005

NKF, 2005
KDIGO, 2012

NKF, 2007
NKF, 2006

KDIGO, 2012

NKF, 2003

KDIGO, 2009

was assessed with Pearsons’ or Spearman’s test according to the normality. A
p-value of less than 0.05 was considered
to be statistically significant for all analyses.
Socio-demographic characteristics of patients included in the study
The number of HD patients was 158
patients; 95 males (60.1%) and 63 females (39.9%). Age was between 18-92
years, the mean age was 49.6±18.0
years. The mean weights before and after dialysis were 72.87±20.0 kg and
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70.60±19.5 kg respectively,
mean height was 166±8.9 cm.

and

the

All the patients were from Hebron
region, 75 (47.5%) of them were from
the city, 82 (51.9%) were from the villages, and only one patient was (0.6%)
from a camp.
The highest percentage of participants had a middle school degree
(39.2%). Most of HD patients (90.5%)
were not working and (17.7%) were still
smoking. Socio-demographic characteristics of the patients are presented in
(Table 2).
Table (2): Socio-demographic characteristics
of the 158 patients.
Characteristics
Mean
Age
49±18 years
Weight before
72.87±20 Kg
dialysis
Weight after
70.60±19.5 Kg
dialysis
Height
166±8.9 cm
Characteristics Frequency Percentage
Patients’ gender
Male
95
60.1%
Female
63
39.9%
Living place
City
75
47.5%
Village
82
51.9%
Camp
1
0.6%
Educational level
Primary and
36
22.8%
illiterate
Middle school
62
39.2%
High school
31
19.6%
26
15.6%
University
graduate
Postgraduate
3
1.9%
Working
Yes
15
9.5%
No
143
90.5%
Smoking
Smoker
28
17.7%
Not smoker
130
82.3%

RESULTS
Prescribing pattern for HD patients
During the study period 158 HD patients were prescribed 1567 medication
orders of 103 different medications, 49
medications for the management of
chronic illness, and 54 medications for
acute illness. The patients were taking a
minimum of 2 and a maximum of 18
medications, with a mean of 9.92±2.94
(Figure 1).
The
most
commonly
prescribed
medications
were
calcium
carbonate
(91.8%),
followed
by
alfacalcidol
(84.8%), then iron/folic acid (69.6 %).
The top twenty used medications are
presented in (Table 3).
Table (3): The top twenty used medications
among HD patients (n= 158).
NO

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Medication
Calcium Carbonate
Alfacalcidol
Iron/ folic acid
Amlodipine
Paracetamol
Aspirin
Folic Acid
Atorvastatin
Ranitidine
Insulin Mixtard
Omeprazole
Furosemide
Diclofenac Sodium
Allopurinol
Ceftriaxone
Atenolol
Amoxycillin/Cla
vulanic Acid
Sevelamir
Chlorphenirami
ne
Isosorbide-5Mononitrate

Frequency
145

Percentage (%)
91.8%

134
110
105
76
70
67
63
61
54
50
43
37

84.8%
69.6%
66.5%
48.1%
44.3%
42.4%
39.9%
38.6%
34.2%
31.6%
27.2%
23.4%

32
32
27
25

20.3%
20.3%
17.1%
15.8%

25
24

15.8%
15.2%

22

13.9%
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Figure (1): Number of medications used by the patients.
Dialysis data
In this study there was one patient
who spent 21 years on HD. One month
was the minimum duration, and 252
months was the maximum. The length of
each dialysis session was 180 minute in
most patients 152 (96.2%), other options
were 210, or 240 minutes, and the number of dialysis session per week were 1,
2, 3, and 4. Most of the patients had 3
sessions.
In HD patients, potassium level was
measured for only 68 patients with a
mean of 5.08±0.97 mg/dl and a range of
(2.4-7.1 mg/dl). Blood urea nitrogen
(BUN) and serum creatinine were measured for all patients and the mean was
67.65±24.31mg/dl (range 7.8-169 mg/dl)
and 7.7±2.68 mg/dl (1.3-14.8 mg/dl)
respectively.
Compliance to treatment guidelines for
diabetes
Fifty eight (36.7%) patients were
found to have diabetes. Insulin mixtard
was used by 54 of the patients, four were
taking glibenclamide, three were taking
insulin actrapid and two of them were on
oral metformin. HgA1c was not performed in the hospital, and data about it
was missing and there was no follow up
for it.

Fasting blood sugar levels was tested for all HD patients who had or had
not diabetes and random was tested for
41 patients, only 21 of them were diabetic. Among the 58 patients with diabetes,
25 (43.1%)
patients had fasting blood
sugar test < 130 mg/dl, while random
blood sugar test was performed for 21
diabetic patients, and 9 (42.8%) of them
had their readings below 180 mg/dl. No
statistically significant association between diabetes control and any other
related variable was found.
Compliance to treatment guidelines for
hypertension
Among patients, 114 (72.2%) had hypertension. Many drugs were used to control
their blood pressure such as enalapril, losartan, valsartan, amlodipine, nifedipine,
diltiazm, atenolol, bisoprolol, carvidilol, propranolol, methyldopa, doxazocin, hydrochlorothiazide, and furosemide. Amlodipine was
the most commonly antihypertensive medication used by 105 (66.5%) of the patients.
The target predialysis blood pressure of less than 140/90 mmHg was
achieved in 122 (77.2%) patients (70.5%
of the males vs 87.3% of the females; Pvalue = 0.014). On the other hand,
postdialysis blood pressure of less than
130/80 mmHg was achieved in 91
(57.6%) patients only. There was no statistically significant association between
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postdialysis blood pressure and sociodemographic
and
clinical
variables.
Predialysis blood pressure correlated
with postdialysis blood pressure (r =
0.236, p value = 0.003) based on Pearson’s test.

demographic
found.

Compliance to
for dyslipidemia

There was no data available for calcium, or PTH levels in HD patients. Only phosphorus level was measured but
not for all the patients. Calcium carbonate was used by 145 (91.8%) patients, sevelamir by 25 (15.8%) patients,
and alfacalcidol by 134 (84.8%) patients.
Phosphorus target level of 3.5-5.5 mg/dl
according to the NKF guidelines was
achieved in only 19 (12.0%) patients,
128 (81.0%) had phosphorus levels out
of the target, and 11 (7.0%) of the patients had no data. If serum phosphorus
normal range of 2.5–4.5 mg/dl is used
according to KDIGO guidelines, this
target was achieved in 7 (4.4%) patients
only.

treatment

guidelines

Among the 158 patients, atorvastatin was used by 63 (39.9%), and
rosvastatin, bezafibrate were used in one
patient only. Total cholesterol and triglyceride were tested for the patients.
The
mean
total
cholesterol
was
164±50.24 mg/dl ranging from 65 to 364
mg/dl. Patients with total cholesterol
levels of less than 200 mg/dl were 123
(78.3%) patients from 157 for whom
total cholesterol was measured. Regarding triglycerides levels, they ranged from
43 to 622 mg/dl. The majority of the patients 96.2% had triglycerides levels of
<500 mg/dl. There was an association
between the control of total cholesterol
and triglycerides (Chi-square, p value =
0.006).
Compliance
for anemia

to

treatment

guidelines

Iron was used by 110 (69.9%) patients, and erythropoietin by 8 (5.1%)
patients only. Mean hemoglobin level
was 8.84±1.52 mg/dl with a range (5.814.4 mg/dl), Patients who reached goal
Hb of 11-12 mg/dl according to the NKF
guidelines were 14 (8.9%) patients only.
If KDIGO guidelines are used, these
guidelines accept a Hb level between 911.5 mg/dl but not to exceed 13 mg/dl,
the patients in this range reach 68
(43.0%) cases.
Target ferittin level of > 200 ng/ml
according to NKF guidelines was
achieved in 91 (57.6%) patients. Target
ferittin level of > 500 ng/ml according to
KDIGO guidelines was achieved in 74
(46.8%) cases. There were no data available about ferittin level for 51 (32.3%)
patients. Transferin test was not performed for all the patients.
No statistically significant association between anemia control and socio-

or

clinical

Compliance to treatment
for bone mineral disorder

factors

was

guidelines

DISCUSSION
In this study, the 158 HD patients were
prescribed 1567 medications of 103 different
drugs with a mean of 9.92±2.94. The number
of medications in this study is close to other
studies that included CKD and ESRD patients where the mean was around 9 medications (9, 10). However, this is lower than a
study from the USA where the mean of medications prescribed for HD patient reached
12.3 ±0.5 medications (11), this may be due
to not following the same guidelines or the
unavailability of some medications in our
hospitals. On the other hand, it was higher
than a Japanese study where the mean was
7.2 medications (12). Polypharmacy is common and expected among HD patients, this
increases the possibility of drug-related problems, and the need for extra counseling and
monitoring.
The
most
commonly
prescribed
medications for HD patients in this study
were calcium carbonate (91.8%), followed by alfacalcidol (84.8%), then
iron/folic acid (69.6 %). This is expected
based on the complications of the disease. A study conducted at a nephrology
unit in a Malaysian hospital showed that
calcium carbonate was the most com-
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monly prescribed medication also, followed by a combination of folic acid and
vitamin B complex, and the third commonly
prescribed
medication
was
metoprolol (9). In a study from India, the
five most commonly prescribed drugs
were multivitamins, iron, folic acid, calcium carbonate, and calcitriol (10).
In this study, 58 (36.7%) patients
had diabetes, among them, 54 were on
mixtard
insulin,
4
were
on
glibenclamide, 3 were on actrapid insulin and 2 were on metformin. According
to the NKF guidelines insulin and
glibenclamide are accepted choices to be
used.
First
generation
sulfonylureas
(e.g., chlorpropamide, tolazamide, and
tolbutamide) should be avoided in patients with CKD because they have increased half-lives and the risk of hypoglycemia. Glipizide is the preferred second-generation sulfonylureas as it does
not have active metabolites and does not
increase the risk of hypoglycemia in patients with CKD (13). Regarding metformin is cleared by the kidneys, so its
use in CKD is restricted. Black-box
warning was mandated by the FDA regarding the risk of lactic acidosis. The
label indicates that metformin should not
be used in men with a SCr of 1.5 mg/dL
or in women with a SCr of 1.4 mg/dl
(13), two patients in this study were prescribed this medication.
The guidelines evaluate diabetes
control according to Hb A1c test. In this
study no HbA1c values were available in
the files and these tests were not performed for diabetic hemodialysis patients. Fasting and random blood glucose
levels were the only available tests. Fasting blood glucose test was done for all
HD patients once every month, it is recommended to test blood glucose frequently for diabetic patients. However,
measuring glucose levels in patients
without diabetes with this frequency
might not be needed. Among the 58 patients with diabetes, 25 (43.1%) patients
had fasting blood sugar test < 130mg/dl,
while random blood sugar test was performed for 21 diabetic patients, and 9

(42.8%) of them had their readings below 180mg/dl. The American Diabetes
Association
recommends
preprandial
plasma glucose of < 130 mg/dl and postprandial levels of < 180 mg/dl for diabetic patients in general (14). It can be
noticed here that more than half of diabetic patients did not achieve these levels. Treatment of diabetes in HD patients
needs to be improved, monitoring of Hb
A1c is needed to guide treatment.
Among patients, 114 (72.2%) of HD
patients had hypertension, this is expected and similar to other parts of the
world where 60% to 90% of maintenance HD patients have hypertension.
Hypertension in these patients often is
poorly controlled despite the use of multiple medications (15, 16).
Amlodipine was the most commonly antihypertensive medication used by
105 (66.5%) of the patients, 11 (7%)
were on enalapril, 5 (3.2%) were on
losartan, and 3 (1.9%) were on valsartan.
This low use of ACE inhibitors and
ARBs is not in agreement with the NKF
recommendations in which drugs that
inhibit the renin angiotensin system are
preferred for the management of hypertension in HD patients to decrease cardiovascular risk (17). In a review by Enam
et al in 2014, they consider betaBlockers, CCBs, ACE inhibitors, and
ARBs as appropriate primary choices for
HD patients (18).
The target predialysis blood pressure of < 140/90 mmHg was achieved in
123 (77.8%) patients, while postdialysis
blood pressure of < 130/80 mmHg was
achieved in 91 (57.6%) patients only.
This is better than recent results from
our country where 33 (51.6%) patients
attained predialysis blood pressure goals
and 31 (48.4%) reached the postdialysis
goal (19). However, there is a room for
improvement. To control blood pressure,
not only medications are important, restrictions in sodium and fluids are recommended. Postdialysis blood pressure
correlated with predialysis values, so if it
is possible to control BP between ses-
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sions, the control will improve after dialysis also.
According to the NKF, LDL cholesterol levels should be below 100 mg/dL,
and statin can be used to achieve this
target. In this study LDL levels were not
tested, instead, total cholesterol and triglycerides were measured; atorvastatin
was used by (39.9%). Patients with total
cholesterol levels of < 200 mg/dl were
123 (78.3%). The majority of the patients 151 out of 157 (96.2%) had triglycerides
levels
of
<500
mg/dl.
Dyslipidemia may increase risk of ischemic stroke and cardiovascular mortality. The control of dyslipidemia in this
study is better than other conditions and
complications as most of the patients had
accepted levels of total cholesterol and
triglycerides, however, it is recommended to test LDL cholesterol and concentrate on dietary counseling.
In this study complete blood count
was done periodically once a month, and
(91.1%) of the HD patients had anemia
defined as Hb levels < 11mg/dl according to the NKF guidelines (20) and even
If KDIGO guidelines are used (21), these guidelines accept a Hb level between
9-11.5 mg/dl but not to exceed 13 mg/dl,
the patients in this range were 68
(43.0%) cases which means that many
patients in the study are anemic. Renal
data from the Arab World, showed that
control of anemia, was not satisfactory
as 50% of study patients had Hb levels <
10 g/dl in 103 HD patients in Libya (22).
According to NKF (20) the ESAs
are critical components in managing the
anemia of CKD, where IV administration is preferred, and effective use of
iron agents, guided by appropriate testing of iron status is recommended. Iron
was used in (69.9%) of the patients, but
erythropoietin IV route was used by 8
(5.1%) out of 158 patients only, as it was
not available during study period in the
hospital due to financial problems in the
MOH, this medication is expensive to be
purchased by the patients. Target ferittin
level of > 200 ng/ml according to NKF
guidelines was achieved in 91 (57.6%)

patients. Target ferittin level of > 500
ng/ml according to KDIGO guidelines
(21) was achieved in 74 (46.8%) cases.
There were no data available about
ferittin level for 51 (32.3%) patients.
Transferin test was not performed for all
the patients. It is clear that better treatment for anemia is recommended and
more investigations are needed.
According to NKF Serum levels of
calcium, phosphorus, and PTH should be
measured in all patients with CKD and
GFR<60 mL/min/1.73m2. A study in
Libya in 2006 found that the target serum level of intact parathyroid hormone
(PTH) was reached in 17.4% of the patients, and only 30% of the patients
achieved target serum calcium (8.4-9.5
mg/dl) (22). But in this study calcium
and parathyroid hormone serum level
were not measured for the patients, because they are not available in the hospital’s laboratory, and are expensive to be
done out in private laboratories. During
this study period only one patient did
these tests on his own account. Almost
all the patients (91.8%) were taking calcium carbonate, in addition to (84.8%)
were taking alfacalcidol to reduce the
serum levels of PTH to a target range of
150 to 300 pg/mL as recommended by
NKF (23). Target phosphorus level of
(3.5-5.5 mg/dl) was reached in (12%) of
the HD patients, and according to
KDIGO guidelines (24), this target was
achieved in 7 (4.4%) patient. Only 25%
of the HD patients were taking phosphate binder sevelamir. Management of
chronic kidney disease mineral and bone
disorder requires interdisciplinary team
interventions that include dietary modification, medications, and adequate dialysis therapy. Optimizing adherence to
diet and medications requires an educated and motivated patient, and patient
support system (25).
In summary, compliance to treatment guidelines was low; to achieve a
good compliance to treatment guidelines
in HD patients, cooperation between
patients, doctors, dietitians and clinical
pharmacists is needed. In each HD de-
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partment a nephrologist, and a clinical
pharmacist should be available to follow
up the patients. All the laboratory test,
and medications to control diabetes, hypertension, dyslipidemia, anemia (especially ESA), and bone mineral disorder
should be available, which is the responsibility of the ministry of health. Following international guidelines in treatment
to reach the recommended goals in the
previous diseases and complications can
improve quality of life of patients and
decrease morbidity and mortality (15,
21).
The first limitation of this study is
that it was performed in dialysis center
in Hebron Governmental Hospital so it
might not be representative to the practice in other dialysis centers in other
hospitals. Another limitation is the unavailability of many medications, and
laboratory tests which are important to
measure compliance to treatment guidelines. The last limitation was the unavailability of national guidelines to compare with and the presence of different
international guidelines.

2)

3)

4)

5)

6)

CONCLUSIONS
This study shows a poor level of
compliance to treatment guidelines according to NKF and KDIGO guidelines
for diabetes, hypertension, dyslipidemia,
anemia, and bone mineral disorder,
where target levels for treatment are not
achieved in many HD patients. The medications are not prescribed optimally to
the patients and many required investigations and laboratory tests are not performed.
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